CN105263325A - 用于降低多发性硬化症中丘脑损伤的拉喹莫德 - Google Patents

用于降低多发性硬化症中丘脑损伤的拉喹莫德 Download PDF

Info

Publication number
CN105263325A
CN105263325A CN201380053184.1A CN201380053184A CN105263325A CN 105263325 A CN105263325 A CN 105263325A CN 201380053184 A CN201380053184 A CN 201380053184A CN 105263325 A CN105263325 A CN 105263325A
Authority
CN
China
Prior art keywords
laquinimod
individuality
methods
multiple sclerosis
thalamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380053184.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263325A8 (zh
Inventor
马西莫·菲莉比
詹卡洛·科米
玛丽亚·阿孙塔·罗卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN105263325A publication Critical patent/CN105263325A/zh
Publication of CN105263325A8 publication Critical patent/CN105263325A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
CN201380053184.1A 2012-10-12 2013-10-09 用于降低多发性硬化症中丘脑损伤的拉喹莫德 Pending CN105263325A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12
US61/713,256 2012-10-12
PCT/US2013/064061 WO2014058979A2 (en) 2012-10-12 2013-10-09 Laquinimod for reducing thalamic damage in multiple sclerosis

Publications (2)

Publication Number Publication Date
CN105263325A true CN105263325A (zh) 2016-01-20
CN105263325A8 CN105263325A8 (zh) 2017-07-14

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380053184.1A Pending CN105263325A (zh) 2012-10-12 2013-10-09 用于降低多发性硬化症中丘脑损伤的拉喹莫德

Country Status (18)

Country Link
US (2) US20140107154A1 (https=)
EP (1) EP2961406A4 (https=)
JP (1) JP2015533163A (https=)
KR (1) KR20150080509A (https=)
CN (1) CN105263325A (https=)
AR (1) AR092993A1 (https=)
AU (2) AU2013329348A1 (https=)
BR (1) BR112015007782A2 (https=)
CA (1) CA2884272A1 (https=)
CL (2) CL2015000732A1 (https=)
EA (1) EA201590726A1 (https=)
HK (1) HK1218865A1 (https=)
IL (1) IL237745A0 (https=)
MX (1) MX2015004564A (https=)
PE (1) PE20151435A1 (https=)
SG (1) SG11201501874TA (https=)
TW (1) TW201420101A (https=)
WO (1) WO2014058979A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
HK1198296A1 (en) 2012-02-16 2015-03-27 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201591507A1 (ru) * 2013-02-15 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза лахинимодом
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
SG10202102198RA (en) * 2016-09-13 2021-04-29 Intekrin Therapeutics Inc Treatment of multiple sclerosis with chs-131
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490077A (zh) * 2006-07-17 2009-07-22 诺瓦提斯公司 用作免疫调节剂的胆汁酸酰胺的磺酰基氨基羰基衍生物
US20100158903A1 (en) * 2008-09-16 2010-06-24 Craig Smith Methods for treating progressive multiple sclerosis
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
US20120142730A1 (en) * 2010-12-07 2012-06-07 Nora Tarcic Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
US20120252758A1 (en) * 2011-03-31 2012-10-04 Martin Youngjin Pettersson Novel Bicyclic Pyridinones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
RS54328B1 (sr) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. Tretman multiple skleroze lakvinimodom
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490077A (zh) * 2006-07-17 2009-07-22 诺瓦提斯公司 用作免疫调节剂的胆汁酸酰胺的磺酰基氨基羰基衍生物
US20100158903A1 (en) * 2008-09-16 2010-06-24 Craig Smith Methods for treating progressive multiple sclerosis
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
US20120142730A1 (en) * 2010-12-07 2012-06-07 Nora Tarcic Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
US20120252758A1 (en) * 2011-03-31 2012-10-04 Martin Youngjin Pettersson Novel Bicyclic Pyridinones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALBERTO CIFELLI ET AL: "Thalamic Neurodegeneration in Multiple Sclerosis", 《ANNALS OF NEUROLOGY》 *
CATHERINE CHO ET LA: "A Lesion of the Anterior Thalamus Producing Dystonic Tremor of the Hand", 《ARCH NEUROL》 *
G COMI ET AL: "Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study", 《THE LANCET》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Also Published As

Publication number Publication date
KR20150080509A (ko) 2015-07-09
EP2961406A4 (en) 2017-01-04
EA201590726A1 (ru) 2015-10-30
US20160296511A1 (en) 2016-10-13
AR092993A1 (es) 2015-05-13
WO2014058979A2 (en) 2014-04-17
AU2017203896A1 (en) 2017-06-29
CL2015000732A1 (es) 2015-08-07
WO2014058979A8 (en) 2015-04-16
US20140107154A1 (en) 2014-04-17
WO2014058979A3 (en) 2015-08-20
PE20151435A1 (es) 2015-10-15
SG11201501874TA (en) 2015-05-28
BR112015007782A2 (pt) 2017-07-04
CL2016002873A1 (es) 2017-04-17
CN105263325A8 (zh) 2017-07-14
CA2884272A1 (en) 2014-04-17
IL237745A0 (en) 2015-05-31
AU2013329348A1 (en) 2015-05-28
JP2015533163A (ja) 2015-11-19
MX2015004564A (es) 2015-07-21
EP2961406A2 (en) 2016-01-06
HK1218865A1 (zh) 2017-03-17
TW201420101A (zh) 2014-06-01

Similar Documents

Publication Publication Date Title
CN103260624B (zh) 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途
CN105263325A (zh) 用于降低多发性硬化症中丘脑损伤的拉喹莫德
DK2442651T3 (en) Treatment of multiple sclerosis with laquinimod
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
JP2017514824A (ja) 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
HK1169563B (en) Treatment of multiple sclerosis with laquinimod

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: International Day of publication

Correct: 20140417

False: 20150820

Number: 03

Volume: 32

CI01 Publication of corrected invention patent application
CI02 Correction of invention patent application

Correction item: International Day of publication

Correct: 20140417

False: 20150820

Number: 03

Page: The title page

Volume: 32

CI02 Correction of invention patent application
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160120

WD01 Invention patent application deemed withdrawn after publication